FDAnews
www.fdanews.com/articles/82364-mologen-submits-report-on-third-quarter-the-course-is-set-on-a-positive-future

MOLOGEN SUBMITS REPORT ON THIRD QUARTER: THE COURSE IS SET ON A POSITIVE FUTURE

November 11, 2005

The third quarter 2005 was marked by crucial decisions for MOLOGEN AG (ISIN DE0006637200) -- decisions that set the course on a positive business development. The company succeeded in obtaining significant production licenses, in initiating promising negotiations with industry partners, and in substantially expanding its liquidity. The operative methods that have thus been introduced are expected to yield visible results in the quarters to come.

Biotech Intelligence (http://www.biotech-intelligence.com/html/html/91e0a7a605c9b886a1a3c475cf162920.html)